Barely Significant
← all phrases

a positive trend

11,006 sentences · 11,006 papers · 20,246 search hits before verification · confirmed specimen

Sighted at

p=0.09

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

Consistent with prior evidence, a positive trend toward the effect of HL interventions on SM is found in disease-specific reviews in chronic conditions such as chronic obstructive pulmonary disease, 33 diabetes, 58 heart failure, 74 as well as in healthy populations. 75 Similarly, a recent systematic review of HL interventions reported a statistically significant effect post-intervention in 72% of the studies. 31 Whereas most studies focus on total SM scores, our study offers a robust and differentiated picture of the efficacy of these interventions by estimating effect sizes at a domain-specific level.
Patients in the cilta-cel group had significantly improved overall response rate, rate of complete response (CR) or better, and overall minimal residual disease (MRD) negativity rate compared to the SOC group (Table), with a positive trend in overall survival (HR, 0.78; 95% CI, 0.5–1.2). 97% and 94% of patients treated in the cilta-cel and SOC groups, respectively, had grade 3/4 adverse events, including infections (27% vs 25%) and cytopenias (94% vs 86%).
In cases in which the TNBC‐RPS was not statistically significant compared to other signatures, a positive trend in the T‐score was observed; this still indicates a better prediction ability when using the TNBC‐RPS as the predictor. 3.4 The TNBC‐RPS predicts NCT response in each clinical stage and grade Although the TNBC‐RPS showed good prediction power in TNBC patients, we were concerned that tumor stage or grade might have confounded these findings; it has been reported that TNBC patients with a more advanced tumor stage or grade tend to have better response to NCT. 59 To evaluate this, we first examined the predictive ability of the TNBC‐RPS in the validation metadata for each tumor stage.
12 , 13 A phase I/II clinical trial (ClinicalTrials.gov: NCT02647359 ) for aniridia was completed but failed to meet the primary endpoint despite showing a positive trend towards functional improvement ( https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-a-corporate-update-301014669.html ).